Organigram Says Germany’s Cannabis Market Could Double — Here’s How It Plans to Capitalize

Germany could become one of the most important growth markets for Organigram Global, as the Canadian cannabis producer uses its acquisition of Sanity Group to build a vertically integrated European operation spanning supply, distribution and patient access.

For Max Schwartz, director of investor relations at Organigram Global, the opportunity begins with a relatively simple calculation: Germany remains a young medical cannabis market with patient penetration well below levels seen in more mature jurisdictions.

“Right now Germany is the second largest federally legal market in the world,” Schwartz told IgniteIt in an exclusive interview. “It’s still a rapidly growing market.”

While Canada’s cannabis market has matured to what Schwartz described as low-single-digit annual growth, Germany remains earlier in its development.

“Roughly one, one and a half percent of the population is registered medical patients,” Schwartz said. “We see in mature markets closer to two, two and a half percent, so the market can basically double over the foreseeable future in the near term.”

That expectation helps explain why Germany has become central to Organigram’s international strategy.

“Germany is the crown jewel in terms of the near-term opportunity,” Schwartz said.

But Organigram isn’t treating Germany as the endpoint.

Through Sanity Group, the company has expanded operations in Poland and Czechia, while Schwartz said Organigram is also monitoring markets including Spain and France, as well as Brazil outside Europe, as governments consider new medical cannabis frameworks or broader reforms.

“We see Germany as sort of like the top of the pyramid,” Schwartz said, “but we think that’s just sort of the near-term low-hanging fruit.”

Sanity Changes Organigram’s European Model

Organigram’s strategy changed materially with Sanity Group.

Before the acquisition, Schwartz said, the company approached international markets largely through individual supply agreements with distributors.

“Before Sanity Group, we had to sort of divide and conquer when it came to supply agreements with various distributors across parts of Europe, Australia, the UK, Germany,” he said.

Organigram had also previously shipped significant volumes of cannabis flower to Israel.

Those arrangements gave the company international exposure but limited its control over what happened after the product left Canada.

Sanity provides something different.

“With Germany, as I said, we become a vertically integrated supply chain,” Schwartz said. “We never used to own the distribution anywhere really other than Canada. So now we own the distribution in Europe.”

That ownership gives Organigram greater visibility into demand and allows it to coordinate supply decisions further down the chain.

“We can plan, forecast, manage brands, manage inventory,” Schwartz said. “We have a lot more visibility into what’s happening on the ground.”

Organigram also acquired something harder to quantify: local regulatory expertise.

Schwartz pointed specifically to Sanity co-founder Finn Hänsel and his relationships with policymakers in Germany and elsewhere in Europe.

“Finn is very well known to the government in Germany and governments around Europe that are considering cannabis legalization,” Schwartz said. “He’s very plugged in, and that is an asset for us when we are dealing with local governments who all have slightly different approaches to cannabis legalization.”

Revenue Is Already Growing

The strategic thesis is beginning to show up in Sanity’s revenue, according to Schwartz.

“When we bought Sanity Group, we reported that their Q4 2025 came in at 19 million euros,” he said. “This last full quarter under Sanity Group was 25.5 million euros, so that’s a 34, 35 percent growth rate over just a couple of quarters.”

For Organigram, however, the next stage isn’t only about pushing the top line higher.

Schwartz said he sees opportunities to reduce expenses at both Sanity and Organigram while improving the efficiency of the Canadian operation.

“I think Sanity can mitigate some of their expenses, as does Organigram,” he said. “So I think that there’s a margin improvement on the SG&A side.”

At the same time, he said greater operational efficiency in Canada could support gross-margin improvement in Organigram’s core business.

That combination — international revenue growth, European distribution and potential margin improvement — is what makes Sanity strategically significant rather than simply another overseas sales channel.

Building a Moat in Medical Cannabis

Schwartz also believes international medical cannabis may prove harder for competitors to enter than Canada’s recreational market was during legalization.

“I believe that medical markets have a bit more of a moat than what we saw happen in Canada, where it was sort of the green rush, everyone rushing in at the same time,” he said.

Germany requires more than simply having cannabis available to sell.

“I think it was more difficult to establish a business, say, in Germany, where you had to have the regulatory expertise and sort of the clout to build a business,” Schwartz said.

Sanity’s infrastructure illustrates that barrier.

Schwartz pointed to the company’s telemedicine platform and established distribution network as assets that would take time for a new entrant to replicate.

“Building that telemedicine platform and getting all of their distribution lined up, that is harder to do, say, in Germany than it was in Canada,” he said.

EU-GMP compliance represents another competitive advantage, but Schwartz ultimately expects competition to extend beyond regulatory infrastructure.

“In the long term, I think it’s quality,” he said.

Organigram has invested in genetics, seed-based technology and sensory research designed to improve consistency and understand how different cultivars perform.

That matters because Schwartz expects medical cannabis markets to become increasingly differentiated rather than treating flower as an interchangeable commodity.

“I think that’s the kind of differentiation that we’re going to see in flower markets in international medical markets,” he said.

For Organigram, the bet on Germany therefore extends beyond exporting more Canadian cannabis.

The company is attempting to own more of the infrastructure connecting cultivation to the European patient: compliant production, distribution, inventory management, brands, telemedicine and regulatory relationships.

If Schwartz’s patient-adoption thesis proves correct, Organigram won’t need Germany to become a recreational cannabis market for the opportunity to expand substantially.

Germany’s Growth Story Comes With a Reimbursement Shift

Germany’s growth opportunity is not without regulatory complications. As of July 30, dried cannabis flower is no longer covered under the country’s statutory health insurance benefit, forcing affected patients who want to remain on flower to move to private prescriptions and pay out of pocket. The change has raised concerns about pricing and margins, but the reimbursed flower channel represents a relatively small portion of overall German demand. An analysis by Cannamedical Pharma’s Alfredo Pascual, cited by IgniteIt, estimated that publicly reimbursed flower accounted for roughly 3% to 4% of German market volume in 2025.

That distinction matters for Organigram’s broader growth thesis. If most affected patients migrate to the self-pay market, overall flower demand could prove relatively resilient even as the economics shift within the supply chain. Organigram could also be better positioned to navigate that shift through scale and Sanity Group’s vertically integrated European infrastructure, which gives the company greater control over distribution, inventory, and supply planning. In a market where reimbursement changes could put pressure on pricing and margins, that scale may become increasingly important.